Mon, 18.07.2022 @18:00
in Seminar Room Oppenheim and Zoom
[add to iCal]
About the event
|Lorenz M. Mayr
Chief Executive Officer
Vector BioPharma uses highly engineered adenoviral vectors to achieve cell- and tissue-specfic delivery and tunable expression of genes & and gene regulators with unprecedented precision. The company is using technology developed in the lab of Professor Andreas Plückthun, University of Zurich. We will hear from Lorenz how the company got funded, how operations got started at Technologiepark Basel and what critical milestones in company creation and funding had to be achieved. Nicole will talk about the learnings of her own transition from academia to early stage Biotech and she will also present on some key applications of this widely usable platform technology for future cell/gene therapy, immuno-oncology and other areas.
For registration, please log in and book your place below.
The event will be held in a hybrid format: the speakers will join us in the Oppenheim seminar room at D-BSSE and stay around for further networking over an apero. For people who prefer to attend virtually, there will be a live stream on Zoom. Please note in your registration if you would like to attend the event in person. The number of spaces in the seminar room is limited and will be given on a first-come-first-serve basis – so be quick and make your registration right away!
If you are not affiliated with any Swiss university and would like to register for this event, please e-mail us (firstname.lastname@example.org) or use our contact form.
All registered users will receive the Zoom webinar link via e-mail shortly before the event.
In case you experience problems with the registration tool please contact us at email@example.com.
BOOKINGSInformation about the booking process on the "Next Events" tab!
Bookings are closed for this event.